Advertisement

Assessment and Care of Oral Lesions for Patients Who Undergo Radioiodine Treatment for Thyroid Cancer

      Abstract

      Patients with differentiated thyroid cancer who undergo radioiodine treatment often present oral complications with a significant impact on their oral cavity function. Any potential sources of systemic infections like periodontal disease, unfitted dentures, orthodontic appliances, deficient/rough fillings, or traumatic dentition must be treated by the dental practitioner, because they represent the main source of spread and dissemination. Any systemic complication of a dental foci may result from improper dental preparation of the patient before radioiodine therapy and inadequate post-radioiodine therapy oral care. Therefore, all patients proceeding into radioiodine treatment should be addressed by the oncological team to undergo thorough dental check-up and receive appropriate treatment in due time.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to The American Journal of the Medical Sciences
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Siegel R.
        • Miller K.
        • Jemal A
        Cancer statistics, 2015.
        CA Cancer J Clin. 2015; 65: 29https://doi.org/10.3322/caac.21254
      1. IARC. Globocan 2012. Http://Www-DepIarcFr/. 2016;GLOBOCAN:2012-2013. www-dep.iarc.fr.

        • WHO
        Thyroid Cancer World Health Organization classification.
        2004 (Available at:http://www.pathologyoutlines.com/topic/thyroidwho.html. Accessed August 10, 2020)
        • Tirrò E.
        • Martorana F.
        • Romano C.
        • et al.
        Molecular alterations in thyroid cancer: from bench to clinical practice.
        Genes (Basel). 2019; 10https://doi.org/10.3390/genes10090709
        • Pacini F.
        • Schlumberger M.
        • Dralle H.
        • et al.
        European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium.
        Eur J Endocrinol. 2006; 154: 787-803https://doi.org/10.1530/eje.1.02158
        • Piciu D.
        • Irimie A.
        • Piciu A
        Investigation of thyroid carcinoma over 40 years, using the database of the ion chiricuta institute of oncology Cluj-Napoca.
        J BUON. 2014; 19: 524-529
        • Piciu D
        Thyroid cancer incidence 25 years after Chernobyl, in a Romanian cancer center: is it a public health problem?.
        Curr Radiopharm. 2013; 6: 249-252https://doi.org/10.2174/1874471006666140109114218
        • Muntean V.
        • Domsa I.
        • Zolog A.
        • et al.
        Incidental papillary thyroid microcarcinoma: is completion surgery required.
        Chirurgia (Bucur). 2013; 108: 490-497
        • Mandel S.J.
        • Mandel L.
        Radioactive iodine and the salivary glands.
        Thyroid. 2003; 13: 265-271https://doi.org/10.1089/105072503321582060
        • Almeida J.P.
        • Kowalski L.P
        Pilocarpina no tratamento de xerostomia em pacientes submetidos à iodoterapia: estudo piloto.
        Braz J Otorhinolaryngol. 2010; 76 (Available at: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1808-86942010000500021&nrm=iso. Accessed August 10, 2020): 659-662
        • Lee H.N.
        • An J.Y.
        • Lee K.M.
        • Kim E.J.
        • Choi W.S.
        • Kim D.Y
        Salivary gland dysfunction after radioactive iodine (I-131) therapy in patients following total thyroidectomy: emphasis on radioactive iodine therapy dose.
        Clin Imaging. 2015; 39: 396-400https://doi.org/10.1016/j.clinimag.2014.12.018
        • Hovan A.J.
        • Williams P.M.
        • Stevenson-Moore P.
        • et al.
        A systematic review of dysgeusia induced by cancer therapies.
        Support Care Cancer Off J Multinatl Assoc Support Care Cancer. 2010; 18: 1081-1087https://doi.org/10.1007/s00520-010-0902-1
        • Jonklaas J
        Nasal symptoms after radioiodine therapy: a rarely described side effect with similar frequency to lacrimal dysfunction.
        Thyroid. 2014; 24: 1806-1814https://doi.org/10.1089/thy.2014.0162
        • Lee S.L.
        Complications of radioactive iodine treatment of thyroid carcinoma.
        J Natl Compr Canc Netw. 2010; 8 (quiz 1287): 1277-1286https://doi.org/10.6004/jnccn.2010.0094
        • Badam R.K.
        • Suram J.
        • Babu D.B.G.
        • et al.
        Assessment of salivary gland function using salivary scintigraphy in pre and post radioactive iodine therapy in diagnosed thyroid carcinoma patients.
        J Clin Diagn Res. 2016; 10 (ZC60-2)https://doi.org/10.7860/JCDR/2016/16091.7121
        • Rodrigues M.
        • Havlik E.
        • Peskar B.
        • Sinzinger H
        Prostaglandins as biochemical markers of radiation injury to the salivary glands after iodine-131 therapy?.
        Eur J Nucl Med. 1998; 25: 265-269https://doi.org/10.1007/s002590050227
        • Epstein J.B.
        • Beier Jensen S
        Management of hyposalivation and xerostomia: criteria for treatment strategies.
        Compend Contin Educ Dent. 2015; 36: 600-603
        • Wainwright W.W.
        • Butt B.G.
        • Hauptfuehrer J.D.
        • Dute H.L
        Deposition of radioactive iodine in teeth of persons treated for disease of the thyroid gland.
        J Am Dent Assoc. 1953; 47: 649-655https://doi.org/10.14219/jada.archive.1953.0219
        • Burlison J.S.
        • Hartshorne M.F.
        • Voda A.M.
        • Cocks F.H.
        • Fair J.R
        SPECT/CT localization of oral radioiodine activity: a retrospective study and in-vitro assessment.
        Nucl Med Commun. 2013; 34: 1216-1222https://doi.org/10.1097/MNM.0000000000000004
        • Fard-Esfahani A.
        • Emami-Ardekani A.
        • Fallahi B.
        • et al.
        Adverse effects of radioactive iodine-131 treatment for differentiated thyroid carcinoma.
        Nucl Med Commun. 2014; 35: 808-817https://doi.org/10.1097/MNM.0000000000000132
        • Daniel F.I.
        • Lima L.D.
        • Grando L.J.
        • Castro R.
        • Cordeiro E.A.K.
        • Dos Santos C.R
        Salivary evaluation in radioactive I(131) treated patients with thyroid carcinoma.
        Acta Odontol Scand. 2018; 76: 148-152https://doi.org/10.1080/00016357.2017.1399214
        • Aframian D.J.
        • Nahlieli O.
        • Knopf A.
        • Lukach L.
        • Qawasmeh N.
        • Nadler C
        Preserving formerly impaired salivary gland function in radioiodine-treated thyroid papillary carcinoma.
        Quintessence Int. 2013; 44: 439-444https://doi.org/10.3290/j.qi.a29186
        • Elad S.
        • Raber-Durlacher J.E.
        • Brennan M.T.
        • et al.
        Basic oral care for hematology-oncology patients and hematopoietic stem cell transplantation recipients: a position paper from the joint task force of the multinational association of supportive care in cancer/international society of oral oncology (MASCC.
        Support Care Cancer. 2015; 23: 223-236https://doi.org/10.1007/s00520-014-2378-x
        • Hong C.H.L.
        • Napenas J.J.
        • Hodgson B.D.
        • et al.
        A systematic review of dental disease in patients undergoing cancer therapy.
        Support Care Cancer. 2010; 18: 1007-1021https://doi.org/10.1007/s00520-010-0873-2
        • Boguslawska-Kapala A.
        • Halaburda K.
        • Rusyan E.
        • Golabek H.
        • Struzycka I
        Oral health of adult patients undergoing hematopoietic cell transplantation. Pre-transplant assessment and care.
        Ann Hematol. 2017; 96: 1135-1145https://doi.org/10.1007/s00277-017-2932-y
      2. MD R., Sandow P., Mendenhall W., MD M. Management of xerostomia, taste impairment and dental prophlaxis. In:; 2005:281–283. doi:10.1007/0-387-25714-4_36

        • Walter M.A.
        • Turtschi C.P.
        • Schindler C.
        • Minnig P.
        • Muller-Brand J.
        • Muller B
        The dental safety profile of high-dose radioiodine therapy for thyroid cancer: long-term results of a longitudinal cohort study.
        J Nucl Med. 2007; 48: 1620-1625https://doi.org/10.2967/jnumed.107.042192
        • Rosales AC de MN
        • Esteves S.C.B.
        • Jorge J.
        • Almeida OP de
        • Lopes M.A
        Dental needs in Brazilian patients subjected to head and neck radiotherapy.
        Braz Dent J. 2009; 20: 74-77https://doi.org/10.1590/s0103-64402009000100013
        • Irie M.-.S.
        • Mendes E.-.M.
        • Borges J.-.S.
        • Osuna L-G-G
        • Rabelo G.-.D.
        • Soares P.-.B.-.F
        Periodontal therapy for patients before and after radiotherapy: a review of the literature and topics of interest for clinicians.
        Med Oral Patol Oral Cir Bucal. 2018; 23: e524-e530https://doi.org/10.4317/medoral.22474
        • Malmberg L.
        • Bjorkner A.E.
        • Bergenholtz G
        Establishment and maintenance of asepsis in endodontics - a review of the Literature.
        Acta Odontol Scand. 2016; 74: 431-435https://doi.org/10.1080/00016357.2016.1195508
        • Zero D.T
        Dentifrices, mouthwashes, and remineralization/caries arrestment strategies.
        BMC Oral Health. 2006; 6: S9https://doi.org/10.1186/1472-6831-6-S1-S9
      3. Professionally applied topical fluoride: evidence-based clinical recommendations.
        J Am Dent Assoc. 2006; 137: 1151-1159https://doi.org/10.14219/jada.archive.2006.0356
        • Busaidy N.L.
        • Cabanillas M.E
        Differentiated thyroid cancer: management of patients with radioiodine nonresponsive disease.
        J Thyroid Res. 2012; 2012618985https://doi.org/10.1155/2012/618985
        • Sisson J.C.
        • Freitas J.
        • McDougall I.R.
        • et al.
        Radiation safety in the treatment of patients with thyroid diseases by radioiodine 131I : practice recommendations of the American Thyroid Association.
        Thyroid. 2011; 21: 335-346https://doi.org/10.1089/thy.2010.0403
        • Gomes-Lima C.J.
        • Wu D.
        • Kharazi P.H.
        • et al.
        Selected radiation safety aspects including transportation and lodging after outpatient (131)I therapy for differentiated thyroid cancer.
        Thyroid. 2017; 27: 1558-1565https://doi.org/10.1089/thy.2017.0124